Compare SUVEN LIFE with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUVEN LIFESCIENCES vs VENUS REMEDIES - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUVEN LIFESCIENCES VENUS REMEDIES SUVEN LIFESCIENCES/
VENUS REMEDIES
 
P/E (TTM) x 1.3 -1.1 - View Chart
P/BV x 0.3 0.1 430.6% View Chart
Dividend Yield % 7.4 0.0 -  

Financials

 SUVEN LIFESCIENCES   VENUS REMEDIES
EQUITY SHARE DATA
    SUVEN LIFESCIENCES
Mar-19
VENUS REMEDIES
Mar-18
SUVEN LIFESCIENCES/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs338126 268.2%   
Low Rs16961 277.3%   
Sales per share (Unadj.) Rs52.1301.8 17.3%  
Earnings per share (Unadj.) Rs6.8-24.9 -27.5%  
Cash flow per share (Unadj.) Rs8.62.5 336.8%  
Dividends per share (Unadj.) Rs1.500-  
Dividend yield (eoy) %0.60-  
Book value per share (Unadj.) Rs65.3293.3 22.3%  
Shares outstanding (eoy) m127.2812.34 1,031.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.90.3 1,569.9%   
Avg P/E ratio x37.1-3.8 -987.3%  
P/CF ratio (eoy) x29.636.7 80.5%  
Price / Book Value ratio x3.90.3 1,218.2%  
Dividend payout %22.00-   
Avg Mkt Cap Rs m32,2721,154 2,797.0%   
No. of employees `0001.10.9 117.0%   
Total wages/salary Rs m661393 168.2%   
Avg. sales/employee Rs Th6,132.24,026.1 152.3%   
Avg. wages/employee Rs Th611.1425.0 143.8%   
Avg. net profit/employee Rs Th803.5-331.8 -242.2%   
INCOME DATA
Net Sales Rs m6,6353,724 178.2%  
Other income Rs m24223 1,076.8%   
Total revenues Rs m6,8773,747 183.6%   
Gross profit Rs m1,604395 406.3%  
Depreciation Rs m221338 65.4%   
Interest Rs m38354 10.6%   
Profit before tax Rs m1,587-275 -576.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m71832 2,272.1%   
Profit after tax Rs m869-307 -283.3%  
Gross profit margin %24.210.6 228.1%  
Effective tax rate %45.2-11.5 -394.0%   
Net profit margin %13.1-8.2 -159.0%  
BALANCE SHEET DATA
Current assets Rs m6,2322,638 236.3%   
Current liabilities Rs m1,4902,305 64.7%   
Net working cap to sales %71.58.9 799.2%  
Current ratio x4.21.1 365.4%  
Inventory Days Days86135 63.8%  
Debtors Days Days8346 178.3%  
Net fixed assets Rs m4,0434,871 83.0%   
Share capital Rs m127123 103.2%   
"Free" reserves Rs m8,1833,496 234.1%   
Net worth Rs m8,3103,619 229.6%   
Long term debt Rs m181,374 1.3%   
Total assets Rs m10,3897,509 138.4%  
Interest coverage x43.10.2 19,332.3%   
Debt to equity ratio x00.4 0.6%  
Sales to assets ratio x0.60.5 128.8%   
Return on assets %8.70.6 1,383.1%  
Return on equity %10.5-8.5 -123.4%  
Return on capital %19.51.6 1,233.5%  
Exports to sales %00-   
Imports to sales %013.9 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA517 0.0%   
Fx inflow Rs m5,6220-   
Fx outflow Rs m1,799517 348.4%   
Net fx Rs m3,822-517 -740.0%   
CASH FLOW
From Operations Rs m356514 69.1%  
From Investments Rs m-279-123 226.3%  
From Financial Activity Rs m-225-387 58.2%  
Net Cashflow Rs m-1484 -3,528.6%  

Share Holding

Indian Promoters % 63.4 32.9 193.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 0.2 -  
FIIs % 0.0 0.6 -  
ADR/GDR % 0.0 0.0 -  
Free float % 36.5 66.4 55.0%  
Shareholders   37,287 20,121 185.3%  
Pledged promoter(s) holding % 0.0 36.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUVEN LIFESCIENCES With:   NATCO PHARMA  FRESENIUS KABI ONCO.  GLENMARK PHARMA  TORRENT PHARMA  PANACEA BIOTECH  

Compare SUVEN LIFESCIENCES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Crashes 1,203 Points; IT and Banking Stocks Witness Selling(Closing)

Indian share markets extended losses in the first trading session of FY21, as the number of coronavirus cases in the country continued to rise.

Related Views on News

SUVEN LIFESCIENCES Announces Quarterly Results (1QFY20); Net Profit Up 47.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 572 m (up 47.2% YoY). Sales on the other hand came in at Rs 2 bn (up 3.8% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

SUVEN LIFESCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 22, 2019 | Updated on Jul 22, 2019

Here's an analysis of the annual report of SUVEN LIFESCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUVEN LIFESCIENCES. Also includes updates on the valuation of SUVEN LIFESCIENCES.

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

SUVEN LIFESCIENCES Announces Quarterly Results (4QFY19); Net Profit Up 8.7% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 680 m (up 8.7% YoY). Sales on the other hand came in at Rs 3 bn (up 18.5% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

VENUS REMEDIES Announces Quarterly Results (3QFY19); Net Profit Down 2301.8% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, VENUS REMEDIES has posted a net profit of Rs 119 m (down 2301.8% YoY). Sales on the other hand came in at Rs 691 m (down 25.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

More Views on News

Most Popular

Sorry Warren Buffett, I'm Following This Man Instead of You in 2020(The 5 Minute Wrapup)

Mar 30, 2020

This man warned of an impending market correction while everyone else was celebrating the renewed optimism in early 2020...

A Big Trading Opportunity is Coming Your Way Soon(Fast Profits Daily)

Mar 25, 2020

I see a big opportunity to make fast profits on the horizon.

The Biggest Trading Opportunity of 2020 is Here...

Mar 26, 2020

India's #1 trader, Vijay Bhambwani, talks about a hugely profitable trading opportunity which you must know about today!

Coronavirus Sell-off Is a Perfect Time to 'Lockdown' this 'Crorepati' Stock(Profit Hunter)

Mar 24, 2020

Coronavirus crisis and panic selling has brought this quality smallcap to multiyear lows, making it a great bargain.

Lockdown! Now the Bailout...(The Honest Truth)

Mar 25, 2020

Ajit Dayal on what India should do to manage the coronavirus impact on the economy.

More

How to Trade the
Coronavirus Crash

Coronavirus Crash
Get this special report, authored by Equitymaster's top analysts, now.
We will never sell or rent your email id.
Please read our Terms

SUVEN LIFESCIENCES SHARE PRICE


Apr 1, 2020 (Close)

TRACK SUVEN LIFESCIENCES

  • Track your investment in SUVEN LIFESCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON SUVEN LIFESCIENCES

SUVEN LIFESCIENCES 8-QTR ANALYSIS

COMPARE SUVEN LIFESCIENCES WITH

MARKET STATS